Latest from Dan L. Duncan

Supported by research, there have been recent developments in using scalp cooling to combat chemotherapy-induced alopecia for patients with breast cancer.
C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.
Mothaffar F. Rimawi, MD, associate professor and medical director at the Lester and Sue Smith Breast Center at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, discusses the findings of the NSABP B-52 trial, which explored the addition of neoadjuvant estrogen deprivation therapy to docetaxel and carboplatin plus the HER2 inhibitors trastuzumab (Herceptin) and pertuzumab (Perjeta) as treatment for patients with HER2-positive breast cancer.
Some HER2-positive breast cancer patients may be able to receive targeted neoadjuvant therapy with lapatinib and trastuzumab without chemotherapy.
Publication Bottom Border
Border Publication